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Background: Second-line chemotherapy offers advanced non-small 
cell lung cancer (NSCLC) patients a small but signiﬁcant survival 
improvement. Docetaxel is usually administered as a 3-week schedule. 
But it has a high toxicity burden. Therefore, weekly schedule has been 
explored in several trials. In this retrospective study, we compared the 
efﬁcacy and safety of weekly schedule and 3-week schedule docetaxel 
monotherapy as a second-line setting.
Methods: Docetaxel was administered with 75 mg/m2 on day 1 every 3 
week or 37.5 mg/m2 on day 1, 8 every 3 week until disease progression 
or severe toxicity developed.
Results: From October 2003 to March 2006, a total 38 patients 
received docetaxel monotherapy and 37 patients can be evaluated. A 
total 141 cycles were administered and evaluated. The median overall 
survival was 13.3 months (95% Conﬁdence interval; 6.3 ~ 20.3) in 
the weekly schedule and 10.7 months (95% Conﬁdence interval; 8.3 ~ 
13.0) in the 3-week schedule (p=0.41). The median time to progression 
was 3.0 months (95% Conﬁdence interval; 1.9 ~ 4.0) and 2.8 months 
(95% Conﬁdence interval; 1.0 ~ 4.6), respectively (p=0.41). Response 
rate was 16.7% in weekly schedule and 21.1% in the 3-week schedule. 
Major hematologic toxicity was grade 3-4 neutropenia (3-week: 39.2%, 
weekly: 11.9%). Non-hematologic toxicities were similar between the 
two schedules. There were no treatment-related deaths.
Conclusions: Docetaxel weekly schedule is very well tolerable and 
comparable activity with 3-week schedule. Considering efﬁcacy and 
tolerability, it can be alternative schedule of standard treatment as a 
second-line setting. 
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Background: We have previously shown the optimal dose of biweekly 
Gemcitabine and Paclitaxel (GEM/PAC) for the treatment of refractory 
and/or resistant patients with non-small cell lung cancer (NSCLC). 
We conducted a phase II study of this combination chemotherapy to 
evaluate the efﬁcacy and safety of biweekly GEM/PAC in patients with 
NSCLC as a second line chemotherapy after platinum-based chemo-
therapy.
Methods: Patients with measurable tumor who had received one previ-
ous chemotherapy or chemotherapy/radiation regimen were eligible. 
PAC (150mg/m2) was administered ﬁrst over one hour followed by 
GEM (1000mg/m2) over 30minutes and repeated biweekly at least 4 
cycles.
Results: Thirty-one patients were enrolled, median age of 64 yr (range 
39 to 75). Nine were female and twenty-two were male. Stage 3b was 
eleven and Stage 4 was twenty. Thirteen patients had a performance 
status 0, sixteen were 1, and two were 2. Twenty-six patients (84%) 
were received with platinum compound plus Docetaxel regimen. Bi-
weekly GEM/PAC was performed with the median cycles of 5.2 (1-20 
cycles). Partial response observed in seven cases (23%), and stable 
disease was seen in eighteen (58%). Median survival time after GEM/
PAC was seven months. Over grade 3 or 4 hematological toxicity (3%) 
and neurotoxicity (3%) were observed in one patient, respectively. One 
patient who received only one cycle of this chemotherapy developed 
pulmonary toxicities, resulted in fatal respiratory failure.
Conclusions: The biweekly GEM/PAC combination chemotherapy 
was active and well tolerated as a second-line therapy in patients with 
NSCLC. Paclitaxel might be a promising and alternative agent in pa-
tient with previously treated with Docetaxel as ﬁrst line.
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In our study, patients who were diagnosed as local advanced NSCLC 
and treated with gemsitabine plus cisplatine (GP) regimen, were evalu-
ated retrospectively. 77 patients ( 72 male and 5 women) who were 
taken more then two cycles of GP chemotherapy and reevaluated after 
chemotherapy is admitted to the study. Patients median age was 65. 
Patiens were evaluated with their stages, responce to the chemotheray 
after 2 and 4 th cycle with WHO responce criteria, time to progression, 
toxicity proﬁles and EQRLC quality of life assesment of 24 patents. 
Median chemotherapy cycle is 3 and 5% complete responce, 39% 
partial responce, 30% stable disease, 26% progressive disease were re-
staged after 2 course of chemotherapy. Median survival is 12,5 mounth 
and time to progression is 5 mounth. Neutropenia and anemia are the 
most common hematological toxicities whilst emezis and allopesia are 
the most common nonhematological toxicities .
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Introduction: Sixty percent of all neoplasms and two-thirds of all 
deaths due to cancer occur in persons older than 65 years. More than 
50% of patients with lung cancer are older than 65 years and 30% older 
than 70 years. With more persons surviving to older age treatment of 
the elderly with lung cancer has become an important issue.
Material and Method: All patients 75 years or older with lung cancer 
seen at the Department of Respiratory Medicine and Allergy, Karolin-
ska Hospital from 2003 to 2005 were retrospective reviewed. In all, 
334 patients were analyzed. 
Results: The mean age was 80.5 years, 94 (58.1%) were men. 94% of 
the males and 79% of the females were smokers or former smokers. 
246 (73.6%) had PS 0-2. 9.2% had SCLC, 19.9% adenocarcinoma, 
and 6.7% squamous cell carcinoma. 23.9% had clinical lung cancer 
and the others broncheoalveolar cell carcinoma or low differentiated 
